{"id":390458,"date":"2019-03-27T00:00:00","date_gmt":"2019-03-27T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneim0004-2019-biopharma-crohns-disease-unmet-need-us-eu-2019\/"},"modified":"2026-04-21T05:26:29","modified_gmt":"2026-04-21T05:26:29","slug":"unneim0004-2019-biopharma-crohns-disease-unmet-need-us-eu-2019","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneim0004-2019-biopharma-crohns-disease-unmet-need-us-eu-2019\/","title":{"rendered":"Crohn&#8217;s Disease | Unmet Need | US\/EU | 2019"},"content":{"rendered":"<p><strong>MARKET OUTLOOK<\/strong><\/p>\n<p>Treatment of moderate to severe Crohn\u2019s disease (<abbr title=\"Crohn's disease\">CD<\/abbr>) typically begins with safe, albeit often less-efficacious, conventional agents (e.g., 5-<abbr title=\"aminosalicylate\">ASA<\/abbr>s) and progresses to more-potent drugs, such as immunosuppressants and\/or biologics. The\u00a0<abbr title=\"tumor necrosis factor\">TNF<\/abbr>-\u03b1 inhibitors (e.g., Janssen\u2019s Remicade, AbbVie\u2019s Humira) are the mainstay of biological treatment for moderate to severe\u00a0<abbr title=\"Crohn's disease\">CD<\/abbr>. However, these agents have safety risks and efficacy limitations. Two additional biological agents with novel mechanisms of action (i.e., Takeda\u2019s Entyvio, a\u00a0<abbr title=\"cell adhesion molecule\">CAM<\/abbr>\u00a0inhibitor approved in 2014, and Janssen\u2019s Stelara, an\u00a0<abbr title=\"interleukin\">IL<\/abbr>-12\/23 inhibitor approved in 2016) have expanded the treatment options for moderate to severe\u00a0<abbr title=\"Crohn's disease\">CD<\/abbr>; however, significant need remains, especially for patients refractory to currently available therapies.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What are the treatment drivers and goals for moderate to severe\u00a0<abbr title=\"Crohn's disease\">CD<\/abbr>?<\/li>\n<li>In addition to efficacy, what other drug attributes influence physician prescribing behavior the most, and which attributes have limited impact?<\/li>\n<li>How do\u00a0<abbr title=\"tumor necrosis factor\">TNF<\/abbr>-\u03b1 inhibitors (branded and biosimilars) and novel biologics (i.e., Entyvio and Stelara) perform on treatment drivers and goals?<\/li>\n<li>What are the prevailing areas of high unmet need and hidden opportunity in moderate to severe\u00a0<abbr title=\"Crohn's disease\">CD<\/abbr>?<\/li>\n<li>What trade-offs across different clinical attributes and prices are acceptable to U.S. and European gastroenterologists for a hypothetical new\u00a0<abbr title=\"Crohn's disease\">CD<\/abbr>\u00a0drug?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p>Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. Two market scenarios are profiled in detail by\u00a0<abbr title=\"Decision Resources Group\">DRG<\/abbr>\u00a0experts, and additional customized market scenarios can be evaluated with the corresponding\u00a0<abbr title=\"target product profile\">TPP<\/abbr>\u00a0simulator.<\/p>\n<p><strong>Markets covered:<\/strong>\u00a0United States, United Kingdom, France, Germany<\/p>\n<p><strong>Primary research:\u00a0<\/strong>Survey of 60\u00a0U.S. and 31\u00a0European gastroenterologists fielded in January2019.<\/p>\n<p><strong>Key companies:<\/strong>\u00a0 AbbVie, Galapagos NV, Gilead, Janssen, Merck &#038; Co., Takeda, TiGenix,\u00a0 Boehringer Ingelheim,\u00a0Allergan,\u00a0 Celgene, Roche<\/p>\n<p><strong>Key drugs:\u00a0<\/strong>Humira, Remicade, Entyvio, Stelara, Cimzia, infliximab biosimilars, adalimumab biosimilars<\/p>\n","protected":false},"template":"","class_list":["post-390458","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-crohns-disease","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-931"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390458","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390458\/revisions"}],"predecessor-version":[{"id":576651,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390458\/revisions\/576651"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390458"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}